ACRS — Aclaris Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1557746 ·
Last close
$6.31
Market Cap
$928.83M
52W High
$6.51
52W Low
$4.07
ADV30
1,909,054
Next earnings
2026-11-05
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 1,629,000 176,000 -23,938,000 -21,505,000 179,693,000 19,167,000 55,112,000
Mar 2026 1,996,000 208,000 -22,192,000 -19,824,000 198,720,000 28,660,000 55,071,000
Dec 2025 1,295,000 -174,000 -21,029,000 -19,795,000 160,460,000 19,960,000 57,378,000
Sep 2025 3,299,000 850,000 -16,333,000 -14,614,000 175,534,000 25,256,000 55,434,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,059,000
Investing CF
$3,530,000
Financing CF
$52,294,000
CapEx
$-118,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.58
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,009,113,000
Inventory
Receivables
$4,680,000
ST Investments
$72,389,000
EBIT TTM
$-85,513,000
Pretax Income TTM
$-75,738,000
Interest Exp TTM
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,219,000
EBITDA
$-85,525,000
Free Cash Flow
$-41,970,624
Enterprise Value
$853,838,912
Total Cash
$91,556,000
Total Debt
$1,850,000
Shares Out
147,198,893
Trailing EPS
$-0.58
Book Value
$0.89
ROE
-59.1%
ROA
-29.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 7,826,000 -74,075,000 -64,923,000 160,460,000 57,378,000 -47,113,000
Dec 2024 18,720,000 -52,527,000 -132,065,000 220,327,000 64,773,000 -20,075,000
Dec 2023 31,249,000 -116,314,000 -88,481,000 197,405,000 40,226,000 -78,325,000
Dec 2022 29,752,000 -85,154,000 -86,908,000 254,596,000 56,975,000 -67,567,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.81

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $6.00 · spot: $6.31 · call volume: 230 · put volume: 83
Expected Move to 2026-09-18: ±$1.24 (19.65%) — implied range $5.07$7.55 · ATM straddle on $6.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CLYM Climb Bio, Inc. $941.95M $16.40
AMPH Amphastar Pharmaceuticals, Inc. $915.42M $21.52
OLMA Olema Pharmaceuticals, Inc. $912.60M $10.43
HELP CYBIN INC. $951.24M $13.02
DSGN Design Therapeutics, Inc. $953.12M $15.23

News headlines (Yahoo Finance, 1h cache)

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
2026-08-06 20:35 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 12:20 · Yahoo
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
2026-07-01 12:23 · Yahoo
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
2026-06-04 19:02 · Yahoo
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:30 · Yahoo
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
2026-05-08 12:30 · Yahoo
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
2026-05-04 10:04 · Yahoo
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Ant
2026-04-28 10:30 · Yahoo
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
2026-04-27 20:45 · Yahoo
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
2026-08-10 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.